Page 8 - Managed Care News Today

Ryan Haumschild, PharmD, MS, MBA, and Mary Pak, MD, FACP, consider FDA-approved gene therapies for hemophilia, spinal muscular atrophy, and Duchenne muscular dystrophy, exploring their genetic foundations, the FDA approval process, and considerations for therapeutic value and cost.

Shares of Centene Co. (NYSE:CNC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average […]

Centene Co. (NYSE:CNC – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price […]

Of those who received an infliximab biosimilar, 87.8% were maintained on a single biosimilar without the need to switch to an alternative product.

Fuller & Thaler Asset Management Inc. raised its holdings in shares of Centene Co. (NYSE:CNC – Free Report) by 4.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,945 shares of the company’s stock after purchasing an additional 1,686 shares during the period. Fuller […]

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Exploring the intersection of psychiatry and work.

International law enforcement operation takes down LockBit leak site - SiliconANGLE

Ontario Teachers Pension Plan Board increased its stake in Centene Co. (NYSE:CNC – Free Report) by 16.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,357 shares of the company’s stock after purchasing an additional 11,032 shares during the period. Ontario […]